Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics, pharmacodynamics and safety of apixaban in patients in hemodiafiltration
2019-002353-29Phase 2Terminated
- Sponsor
- Bellvitge Institute for Biomedical Research
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apixaban in nonvalvular atrial fibrillation (NVAF) and chronic kidney disease (CKD), sponsored by Bellvitge Institute for Biomedical Research. Primary endpoint: Plasma concentration of apixaban. Started Jul 2019; status: terminated.
02
Drugs
apixaban
03
Conditions
nonvalvular atrial fibrillation (NVAF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2019-002353-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002353-29.